

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
19 October 2023 (19.10.2023)



(10) International Publication Number
WO 2023/198744 A1

(51) International Patent Classification:

A61K 39/00 (2006.01) C07K 14/81 (2006.01)
C07K 14/00 (2006.01)

(21) International Application Number:

PCT/EP2023/059506

(22) International Filing Date:

12 April 2023 (12.04.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/330,718 13 April 2022 (13.04.2022) US
63/446,520 17 February 2023 (17.02.2023) US

(71) Applicants: TESSA THERAPEUTICS LTD. [SG/SG];

1 HarbourFront Place, #04-08, HarbourFront Tower One,
Singapore 098633 (SG). AGENCY FOR SCIENCE,
TECHNOLOGY AND RESEARCH [SG/SG]; 1
FUSIONOPOLIS WAY, #20-10 Connexis North Tower,
Singapore 138632 (SG).

(71) Applicant (for LS only): CLEGG, Richard Ian [GB/GB];

c/o Mewburn Ellis LLP, Aurora Building, Counterslip, Bris-
tol BS1 6BX (GB).

(72) Inventors: TEO, Pei Yun; c/o TESSA THERAPEUTICS

LTD., 1 Harbour Front Place, #04-08, Harbour Front Tower
One, Singapore 098633 (SG). LOW, Lionel Jianrong; c/
o TESSA THERAPEUTICS LTD., 1 Harbour Front Place,
#04-08, Harbour Front Tower One, Singapore 098633 (SG).
JUNG, Youngrock; c/o TESSA THERAPEUTICS LTD.,
1 Harbour Front Place, #04-08, Harbour Front Tower One,
Singapore 098633 (SG).

(74) Agent: MEWBURN ELLIS LLP; Aurora Building, Coun-

terslip, Bristol BS1 6BX (GB).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,

KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,

GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
— in black and white; the international application as filed
contained color or greyscale and is available for download
from PATENTSCOPE

(54) Title: THERAPEUTIC T CELL PRODUCT




Figure 1

(57) Abstract: Immune cells comprising modification to increase the expression or activity of SERPINB9 are disclosed. Also disclosed are compositions comprising such cells and methods of using such cells and compositions.



WO 2023/198744 A1